Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Scott Sherman

Scott Sherman

Associate Professor, Neuroscience - GIDP | Associate Professor, Neurosurgery | Associate Professor, Physiological Sciences - GIDP | Clinical Instructor | Professor, Neurology | Associate Professor, Physiology | Member of the Graduate Faculty

Collaboration(45)

Helena Morrison
Esther Sternberg
David Besselsen
Marlys Witte
Russell Witte

Page 1 of 9

Grants(39)

Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
Active·2024·$822.1K·
External
Principal Investigator (PI)
stroke rehabilitation, spasticity treatment, drug safety, efficacy evaluation, tolerability assessment
A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects
Active·2024·$303.6K·
External
Principal Investigator (PI)
ketamine, dyskinesia, levodopa, clinical trial, anesthetic infusion
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
Active·2023·$0 / $597.6K·
External
Co-Investigator (COI)
parkinson's disease, dose escalation, clinical trial, neurodegenerative diseases
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson?s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and i
Active·2023·$1.2M / $308.7K·
External
Principal Investigator (PI)
parkinson's disease, dyskinesia, efficacy, safety/tolerability
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport?) in Comparison with Onabotulinumto
Active·2023·$226.2K·
External
Principal Investigator (PI)
clinical safety, efficacy evaluation

Page 1 of 8

Publications(55)

Recent

Evaluation of microglia in a rodent model of Parkinson s disease primed with L-DOPA after sub-anesthetic ketamine treatment.

2021

neuroinflammation, parkinson's disease, ketamine, microglia, l-dopa

Fall Detection with Wearable Sensors: A Hierarchical Attention-based Convolutional Neural Network Approach

2021

machine learning, healthcare, wearable technology, signal processing, fall prevention

Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine.

2020

neuroscience, pharmacology, drug effects, dyskinesia, spectroscopy

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia

2020

opioid glycopeptide, cns penetration, behavioral analysis, levodopa-induced dyskinesia, preclinical model

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia

2020

ketamine, l-dopa-induced dyskinesia, treatment, preclinical evidence, repurposing

Highly-selective mu;opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model

2020

mu-opioid receptor antagonism, l-dopa-induced dyskinesia, rodent model, selective antagonism, dyskinesia

Accuracy of Dopamine Transporter Imaging with I-Ioflupane in Hispanic and Non-Hispanic Patients

2020

dopamine transporter imaging, ethnicity, diagnostic imaging, parkinson's disease, neuroimaging

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.

2019

ketamine, l-dopa-induced dyskinesia, preclinical evidence, treatment, repurposing

The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced L-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia

2018

opioid glycopeptide, nmda receptor antagonist, l-dopa-induced dyskinesia, dopamine receptor

Patterns and Predictors of Depression Treatment among Older Adults with Parkinson's Disease and Depression in Ambulatory Care Settings in the United States

2018

depression treatment, parkinson's disease, older adults, ambulatory care, united states